BioWorld

Dec. 17, 2002

View Archived Issues

MedImmune, Corixa Take Cases To FDA Advisory Committees

While The Street is leaning toward a favorable vote for MedImmune Inc.'s FluMist as an intranasal influenza vaccine, it's not so clear whether Seattle-based Corixa Inc. will get the nod for its cancer drug, Bexxar. (BioWord Today) Read More

CDP 870 Becomes Inhale's 4th PEG Product In Pivotal Trials

Read More

NIH Structural Biologists Dissect AIDS Virus Triple-Threat Infection, Quick Change, Immunity Evasion

Read More

AdipoGenix Lands Deal With J&J For Program In Obesity

Read More

Goodman Named To Replace Zoon As Director Of CBER

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More